Exploratory Study of the Diagnostic Potential of an Innovative Thoracic Vibration Analysis Technique
Key facts
- Who runs it
- University Hospital, Caen
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 270 people enrolled
- Started
- 17 May 2024
- Ended
- 14 Aug 2025
- Type of study
- Interventional, 3 groups
- Treatments tested
- SMC signal recording
- Record updated
- 29 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Cardiac disease OR respiratory failure OR healthy volunteer
- Affiliate to the social security system
- French-speaking
- Patient having been informed of the study and having signed informed
Who cannot take part
- consent.BMI < 17 or BMI > 35
- Patients unable to stand for more than 10 minutes
- Patients unable to remain in apnea for 15 - 20 seconds
- Breast prosthesis wearers
- Wearers of pacemakers and/or defibrillators
- Valve prosthesis wearers
- Patients with difficulty understanding simple instructions (inspiration, expiration, respiratory blockage)
- Patients with severe hearing problems
- Pregnant or breastfeeding woman. A urine pregnancy test will be performed if necessary
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Heart and lung disease are two major causes of hospitalisation and mortality in France (4-8). Together, these two diseases affect several million people in France, either acutely or chronically. They represent a major public health problem in social and economic terms.
Read full original descriptionShow less
Diagnosis of these disorders is often delayed, with acute decompensation preceded by a period of frustrating, non-specific clinical signs (9-12), which delay their discovery. Screening for these conditions in their early stages or diagnosing them in their acute form is crucial, but remains difficult because it requires multiple investigations that are costly and time-consuming (biology, radiology, ECG, etc.). The difficulty of diagnosis, the progressive profile and the ever-increasing frequency of these conditions (environmental and socio-economic factors) have considerably altered the landscape of medical emergencies and contributed to their difficulty.
The availability of a non-invasive technique capable of diagnosing both cardiac and pulmonary disorders without the help of an expert, without direct contact with the patient and without requiring his or her active participation, would be a major advance.
Technological innovations in all fields have always helped to improve patient care.The recent emergence of telemedicine and POCT(US) connected objects (point of care testing, point of care ultrasound)(13,14) is a good illustration of this.
A new technique using ultrasound, developed by the Langevin Institute (Surface Camera Motion) and supported by the start-up Austral Diagnostics, makes it possible, without direct contact with the subject, to record the propagation of thoracic vibrations induced by the functioning of the heart pump and respiratory mechanics.Consequently, any anomaly in the functioning of these organs can cause a change in the thoracic vibration regime and its propagation.
This completely new technique for exploring thoracic vibrations provides a particularly rich signal that has not yet been explored. Under these conditions, the signatures associated with cardiac and/or pulmonary pathologies are not yet perfectly defined.Furthermore, the diagnostic potential of this new technique in the early or acute phases of cardiopulmonary pathologies remains to be assessed.
In this prospective study, we propose to explore the signatures produced by this signal in various cardiac and respiratory pathologies.
The aim is To identify the discriminating criteria of the SMC signal that enable cardiac and pulmonary pathologies to be detected compared with a group of healthy subjects.
The 3 groups in the trial
- Healthy subjects = no cardiac and no pulmonary diseaseTreatment being tested
Healthy subjects who should undergo SMC recording after echocardiography and resporatory exploration. The volunteers do not show any detectable cardiac damage on ultrasound (ejection fraction \>= 50%, no diastolic dysfunction and no structural disease) or any detectable pulmonary damage on ventilatory tests (Forced expiratory volume in the first second (FEV1), diffusing capacity of the lungs for carbon monoxide (DLCO) and total lung capacity (TLC) ≥ 80%) , FEV1/forced vital capacity (FVC) ratio ≥ 70%.
Treatment: SMC signal recording
- Cardiac disease groupTreatment being tested
Patients in this group had heart disease: (i) moderate to severe aortic stenosis (ii) moderate to severe aortic regurgitation (iii) moderate to severe mitral regurgitation (iv) systolic dysfunction (v) or diastolic dysfunction.
Treatment: SMC signal recording
- Respiratory disease:Treatment being tested
(i) Patients with no pulmonary insufficiency : forced expiratory volume in one second (FEV1) and diffusing capacity of the lungs for carbon monoxide (DLCO) and total lung capacity (TLC) ≥ 80% (ii) Patients with moderate pulmonary insufficiency : forced expiratory volume in one second (FEV1) and diffusing capacity of the lungs for carbon monoxide (DLCO) and total lung capacity (TLC) ≥ 50% and \< 80% (iii) Patients with severe forced expiratory volume in one second (FEV1) or diffusing capacity of the lungs for carbon monoxide (DLCO) or total lung capacity (TLC)\< 50%
Treatment: SMC signal recording
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Exploratory Study of the Diagnostic Potential of an Innovative Thoracic Vibration Analysis Technique for Detecting Pulmonary and/or Cardiac
- Publications
- Airborne Ultrasound Surface Motion Camera: Application to Transfer Admittance Chest Imaging.Annals of biomedical engineering, 2026
- Record updated
- 29 July 2026